Phase II trial of dasatinib for patients demonstrating acquired resistance to treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib (E) or gefitinib (G).

被引：0
|
作者：
Johnson, Melissa L. [1 ]
Riely, Gregory J. [1 ]
Rizvi, Naiyer A. [1 ]
Azzoli, Christopher G. [1 ]
Kris, Mark G. [1 ]
Ginsberg, Michelle S. [1 ]
Pao, William [1 ,2 ]
Miller, Vincent A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Vanderbilt Univ, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S687 / S687
页数：1
相关论文
共 50 条
  • [31] Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
    Chou, Wen-Ru
    Shia, Ben-Chang
    Huang, Yen-Chun
    Ho, Chieh-Wen
    Chen, Mingchih
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [32] Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)
    Si, Jinfei
    Gu, Xiaodong
    Wang, Wenxian
    Ying, Shenpeng
    Song, Zhengbo
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (05) : 1624 - 1634
  • [33] Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
    Bunn, Paul A., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) : 2504 - 2505
  • [34] Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance
    Villadolid, Jeryl
    Ersek, Jennifer L.
    Fong, Mei Ka
    Sirianno, Lindsey
    Story, Ellen S.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 576 - 583
  • [35] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [36] Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Shah, Rashmi R.
    Shah, Devron R.
    DRUG SAFETY, 2019, 42 (02) : 181 - 198
  • [37] Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Rashmi R. Shah
    Devron R. Shah
    Drug Safety, 2019, 42 : 181 - 198
  • [38] Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
    Chen, Qi
    Quan, Qi
    Ding, Lingyu
    Hong, Xiangchan
    Zhou, Ningning
    Liang, Ying
    Wu, Haiying
    ONCOTARGET, 2015, 6 (28) : 24904 - 24911
  • [39] Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Wui, Min
    Yuan, Yuan
    Pan, Yue-Yin
    Zhang, Ying
    MOLECULAR MEDICINE REPORTS, 2014, 10 (02) : 931 - 938
  • [40] Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
    Zhuang, Jingqi
    Yu, Yongfeng
    Li, Ziming
    Lu, Shun
    ONCOTARGET, 2017, 8 (32) : 53675 - 53683
12345